LLY stock forecast, quote, news & analysis

Key Takeaways

• Eli Lilly (LLY) gained about 10.6% over the last 30 days, climbing from roughly $1,151 to approximately $1,273 per share.
• The advance was led by sustained demand for the incretin franchise — Mounjaro and Zepbound — alongside early momentum for the newly launched oral GLP-1 medicine, Foundayo.
• Expanded Medicare obesity-drug coverage and strong U.S. prescription trends underpinned volume growth, even as realized prices remained under pressure.
• Analysts lifted price targets heading into third-quarter earnings, signaling expectations for another strong quarterly print.
• Over the trailing quarter, the shares rose about 7%, following a pullback toward the low-$1,100s in early September and a sharp late-period rebound.
• For additional context, explore Lilly's Price Targets, Earnings, and Forecast pages.
• Investors can also explore Trending AI Robots for AI-driven trading insights across thousands of tickers.

Eli Lilly (LLY) Company Overview and Market Position

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1901, it discovers, develops, manufactures, and markets human medicines sold in roughly 90 countries across four therapeutic areas: cardiometabolic health, oncology, immunology, and neuroscience.

The company's flagship incretin franchise — tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity — has become its dominant growth engine, generating roughly two-thirds of quarterly revenue in 2026. Beyond incretins, Lilly markets Verzenio in oncology, Taltz and Ebglyss in immunology, and Kisunla for early symptomatic Alzheimer's disease, while building out next-generation assets such as the oral GLP-1 Foundayo (orforglipron) and the investigational triple agonist retatrutide. Investors follow the stock closely for its outsized revenue growth, deep clinical pipeline, and status as one of the world's most valuable standalone pharmaceutical companies.

Eli Lilly (LLY) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, LLY climbed from a closing price of $1,150.99 on September 23 to $1,273.46 on October 23, a gain of about 10.6%. Much of the move was concentrated in mid-October, when the stock broke decisively above its prior trading range and advanced toward the $1,300 level.

The broader quarterly trend was more measured but still positive. From a closing price of $1,185.87 on July 23 to $1,273.46 on October 23, the shares rose roughly 7.4%. That three-month path was volatile: the stock pulled back toward the low-$1,100s in early September before recovering and accelerating into late October. In short, the 30-day rally represents a re-acceleration after a period of consolidation, rather than an uninterrupted climb.

What Drove LLY Stock Price in the Last 30 Days

The recent advance has been supported by a combination of product momentum, expanding coverage, and rising analyst expectations. Demand for Mounjaro and Zepbound has remained strong, with injectable therapies still capturing a large majority of new patient starts. The launch of Foundayo, Lilly's once-daily oral GLP-1 for obesity, has also gathered pace, with prescription counts climbing sharply after a September price adjustment and broader commercial access.

Expanded U.S. coverage has been a meaningful catalyst. The Medicare obesity-drug program that began in July has broadened patient access, and Zepbound's Medicare patient base has grown to roughly one million people. Ahead of the company's third-quarter earnings report, several sell-side analysts raised their 12-month price targets, reflecting expectations that volume growth would again offset pricing pressure across the incretin portfolio.

Competitive positioning has reinforced sentiment as well. Lilly's tirzepatide franchise has maintained an efficacy advantage over rival obesity medicines, and the company's next-generation pipeline has kept investor focus on the durability of its growth story rather than near-term pricing headwinds.

What Drove LLY Stock Performance Over the Last Quarter

The quarterly trend was shaped by strong financial results and a series of product and strategic milestones. In early August, Lilly reported second-quarter revenue of about $23 billion, up 48% year over year, beating Wall Street estimates and prompting the company to raise its full-year 2026 revenue guidance. Mounjaro and Zepbound led the beat, while the company trimmed the top end of its adjusted earnings outlook to reflect acquisition-related charges.

Beyond earnings, the quarter featured the continued ramp of Foundayo, the start of Medicare obesity-drug coverage, and progress across the pipeline, including late-stage data for retatrutide and label-expansion efforts for medicines such as Jaypirca. Lilly also maintained an active business-development program, announcing a series of acquisitions and partnerships aimed at diversifying growth beyond GLP-1 therapies. These factors supported a constructive tone through the period, even as the stock briefly consolidated in early September.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a much larger ecosystem of automated strategies. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon trend-following systems, allowing traders to compare different automated approaches in one place. For those interested in supplementing their own analysis with algorithmic signals, reviewing the Trending AI Robots page can be a useful starting point.

LLY Stock Forecast Drivers: What Investors Should Watch Next

Several factors are likely to shape investor expectations for LLY going forward. Third-quarter earnings and updated full-year guidance will be closely watched, particularly the balance between prescription-volume growth and realized-price declines across Mounjaro, Zepbound, and Foundayo. The pace of Foundayo's commercial ramp and its regulatory progress in additional indications will also matter.

Beyond quarterly results, investors are likely to monitor late-stage data for retatrutide, further Medicare and Medicaid coverage developments, and manufacturing-capacity expansion. Competitive dynamics remain relevant as well, including the oral Wegovy launch from Novo Nordisk and advancing candidates from smaller biotech firms. Macroeconomic conditions, regulatory changes, and sector rotation can also influence short-term price action. These considerations are informational only and do not constitute investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations